Streetbeat News

Products Services

DIS

Disney announced that ESPN has secured a new 6-year agreement for the entire College Football Playoff (CFP) starting from the 2026-27 season. ESPN will broadcast the CFP National Championship on ABC and offer a MegaCast presentation across ESPN platforms.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 7:18 pm

DIS

Disney, through ESPN, has extended its exclusive media rights agreement with the College Football Playoff (CFP) until the 2031-32 season. This extension includes both an amended 2-year agreement and a new 6-year extension, granting ESPN the right to sublicense a select number of games.

Portfolio Pulse from Happy Mohamed

March 19, 2024 | 7:17 pm

TSLA

Jim Cramer has declared that Tesla Inc (NASDAQ:TSLA) stock has reached its bottom, with a more than 30% decline for the year. He believes the EV market's dismissal is premature and anticipates all will be driving EVs by 2030. Despite recent price cuts impacting margins, Tesla's price increases for Model Y in the U.S. and Europe, along with rising used Tesla car values, could push the stock higher. Cramer's confidence in Tesla's potential recovery was expressed on CNBC's 'Squawk On The Street' and 'Mad Money.'

Portfolio Pulse from Adam Eckert

March 19, 2024 | 7:01 pm

OXY

Occidental Petroleum's CEO, Vicki Hollub, announced that their first direct air carbon capture project is 70% complete, with the first phase expected to start in mid-2025.

Portfolio Pulse from Happy Mohamed

March 19, 2024 | 6:56 pm

FBLG

FibroBiologics shares have seen an increase following the announcement of preliminary proof-of-concept results for a fibroblast-based diabetes treatment. This development indicates progress in their research and potential for future growth in the diabetes treatment market.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 6:51 pm

CRNX

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) reported positive Phase 3 results for paltusotine in treating acromegaly, meeting all primary and secondary endpoints with no serious adverse events. The company plans to submit a New Drug Application to the FDA in H2 2024 for a potential 2025 launch. Following the news, CRNX shares surged 19.30% to $45.23.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 6:48 pm

MRK

Merck & Co Inc (NYSE:MRK) released data from Phase 3 trials of its investigational pneumococcal conjugate vaccine, V116, showing it to be immunogenic across all 21 serotypes in various adult populations. V116 demonstrated higher immune responses for unique serotypes and a comparable safety profile to existing vaccines. Preliminary real-world evidence suggests V116 covers 84% of detected pneumococcal serotypes in adults hospitalized with pneumonia. Merck's stock has an average 1-year price target of $134.25, indicating a potential upside of 10.49%.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 6:42 pm

BA

C

EADSF

EADSY

GM

Boeing Co (NYSE:BA) is currently facing challenges, with discussions on Reddit highlighting its 'too big to fail' status and comparing its situation to historical examples like Citigroup Inc (NYSE:C) and General Motors Co (NYSE:GM). Despite its dominant position alongside Airbus SE (OTCPK: EADSF) (OTCPK: EADSY), Boeing's recovery is uncertain due to production issues and market dynamics.

Portfolio Pulse from Surbhi Jain

March 19, 2024 | 6:40 pm

AAPL

GOOG

IXP

VOX

Google and Apple are reportedly discussing a potential AI partnership involving Google's Gemini AI platform for iOS 18, sparking optimism among analysts. BofA analyst Justin Post reiterated a Buy rating on Alphabet Inc (GOOG, GOOGL) with a $173 price target. The collaboration could enhance iOS with advanced AI features and reinforce Google's AI leadership. However, Apple may still consider other AI providers. The deal's financial terms are undisclosed, but it's expected to involve a technology licensing fee from Apple to Google. Google's stock responded positively to the news, but there's a risk Apple could choose another partner. Investors can also gain exposure to Google through ETFs like VOX and IXP.

Portfolio Pulse from Anusuya Lahiri

March 19, 2024 | 6:39 pm

CERS

Cerus Corporation (NASDAQ:CERS) announced positive topline results for the ReCePI Phase 3 trial of its INTERCEPT Red Blood Cells (RBCs) in complex cardiac surgery patients, meeting its primary efficacy endpoint. The trial demonstrated non-inferiority of INTERCEPT RBCs compared to conventional RBCs in preventing acute kidney injury (AKI), a key indicator of transfusion efficacy. The safety profile was also comparable. Following this news, CERS shares rose by 3.23% to $1.91. Cerus plans to initiate a modular PMA application to the FDA in the second half of 2025.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 6:39 pm